Telomir Pharmaceuticals, Inc. Common Stock (TELO) 10-Year Financial Performance & Capital Metrics

TELO • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

AboutTelomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. It develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy recovery by interrupting and preventing the interleukin-17 induced inflammatory pathways. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. on October 10, 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.Show more

Revenue $0
EBITDA $0 +100.0%
Net Income -$17M -26.5%
EPS (Diluted) -0.56 -27.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -810.18% +22.5%
ROIC -610.42% -228.4%
Debt/Equity 0.15 +394.6%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Low quality earnings: Net income not backed by cash flow
✗Trading more than 30% below 52-week high
✗Expensive at 62.9x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM51.13%

EPS CAGR

10Y-

5Y-

3Y-

TTM53.04%

ROCE

10Y Avg-457.59%

5Y Avg-457.59%

3Y Avg-457.59%

Latest-599.92%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0
Revenue Growth %	-	-	-	-
Cost of Goods Sold+	0	0	0	0
COGS % of Revenue	-	-	-	-
Gross Profit+	0	0	0	0
Gross Margin %	-	-	-	-
Gross Profit Growth %	-	-	-	-
Operating Expenses+	138.13K	854.15K	3.94M	12.24M
OpEx % of Revenue	-	-	-	-
Selling, General & Admin	11.64K	20.94K	600.19K	9.64M
SG&A % of Revenue	-	-	-	-
Research & Development	126.49K	833.21K	1.57M	2.24M
R&D % of Revenue	-	-	-	-
Other Operating Expenses	0	0	1.77M	370.5K
Operating Income+	-138.13K	-854.15K	-3.94M	-12.24M
Operating Margin %	-	-	-	-
Operating Income Growth %	-	-5.18%	-3.62%	-2.11%
EBITDA+	0	0	-11.43M	0
EBITDA Margin %	-	-	-	-
EBITDA Growth %	-	-	-	1%
D&A (Non-Cash Add-back)	138.13K	854.15K	0	12.24M
EBIT	-138.13K	-854.15K	-11.43M	-12.19M
Net Interest Income+	0	0	-1.64M	4.39M
Interest Income	0	0	0	48K
Interest Expense	0	0	1.64M	-4.34M
Other Income/Expense	0	0	-9.13M	-4.29M
Pretax Income+	-138.13K	-854.15K	-13.07M	-16.53M
Pretax Margin %	-	-	-	-
Income Tax+	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%
Net Income+	-138.13K	-854.15K	-13.07M	-16.53M
Net Margin %	-	-	-	-
Net Income Growth %	-	-5.18%	-14.3%	-0.26%
Net Income (Continuing)	-138.13K	-854.15K	-13.07M	-16.53M
Discontinued Operations	0	0	0	0
Minority Interest	0	0	0	0
EPS (Diluted)+	-0.00	-0.03	-0.44	-0.56
EPS Growth %	-	-	-14.28%	-0.27%
EPS (Basic)	-0.00	-0.03	-0.44	-0.56
Diluted Shares Outstanding	29.61M	29.61M	29.61M	29.54M
Basic Shares Outstanding	29.61M	29.61M	29.61M	29.54M
Dividend Payout Ratio	-	-	-	-

Balance Sheet

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	0	48.73K	435.23K	1.32M
Cash & Short-Term Investments	0	1.42K	1.23K	1.27M
Cash Only	0	1.42K	1.23K	1.27M
Short-Term Investments	0	0	0	0
Accounts Receivable	0	0	130K	0
Days Sales Outstanding	-	-	-	-
Inventory	0	0	0	0
Days Inventory Outstanding	-	-	-	-
Other Current Assets	0	47.31K	303.28K	0
Total Non-Current Assets+	55K	0	4.34M	0
Property, Plant & Equipment	0	0	0	0
Fixed Asset Turnover	-	-	-	-
Goodwill	0	0	0	0
Intangible Assets	0	0	0	0
Long-Term Investments	55K	0	0	0
Other Non-Current Assets	0	0	4.34M	0
Total Assets+	55K	48.73K	4.77M	1.32M
Asset Turnover	-	-	-	-
Asset Growth %	-	-0.11%	96.96%	-0.72%
Total Current Liabilities+	138.13K	986.01K	1.34M	680.97K
Accounts Payable	18.73K	404.22K	707.19K	587.54K
Days Payables Outstanding	-	-	-	-
Short-Term Debt	0	581.79K	101K	93.43K
Deferred Revenue (Current)	0	0	0	0
Other Current Liabilities	119.4K	0	527.38K	0
Current Ratio	-	0.05x	0.33x	1.94x
Quick Ratio	-	0.05x	0.33x	1.94x
Cash Conversion Cycle	-	-	-	-
Total Non-Current Liabilities+	0	0	0	0
Long-Term Debt	0	0	0	0
Capital Lease Obligations	0	0	0	0
Deferred Tax Liabilities	0	0	0	0
Other Non-Current Liabilities	0	0	0	0
Total Liabilities	138.13K	986.01K	1.34M	680.97K
Total Debt+	0	581.79K	101K	93.43K
Net Debt	0	580.37K	99.77K	-1.17M
Debt / Equity	-	-	0.03x	0.15x
Debt / EBITDA	-	-	-	-
Net Debt / EBITDA	-	-	-	-
Interest Coverage	-	-	-2.40x	-
Total Equity+	-83.13K	-937.28K	3.44M	643.04K
Equity Growth %	-	-10.27%	4.67%	-0.81%
Book Value per Share	-0.00	-0.03	0.12	0.02
Total Shareholders' Equity	-83.13K	-937.28K	3.44M	643.04K
Common Stock	0	0	0	0
Retained Earnings	-138.13K	-992.28K	-14.06M	-30.6M
Treasury Stock	0	0	0	0
Accumulated OCI	0	0	0	0
Minority Interest	0	0	0	0

Cash Flow

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-119.4K	-468.66K	-3.86M	-5.07M
Operating CF Margin %	-	-	-	-
Operating CF Growth %	-	-2.93%	-7.24%	-0.31%
Net Income	-138.13K	-854.15K	-13.07M	-16.53M
Depreciation & Amortization	0	0	0	4.34M
Stock-Based Compensation	0	0	0	6.87M
Deferred Taxes	0	0	0	0
Other Non-Cash Items	0	0	9.1M	130K
Working Capital Changes	18.73K	385.49K	113.84K	126.47K
Change in Receivables	0	0	0	0
Change in Inventory	0	0	0	0
Change in Payables	18.73K	0	114.56K	183.63K
Cash from Investing+	0	0	0	0
Capital Expenditures	0	0	0	0
CapEx % of Revenue	-	-	-	-
Acquisitions	-	-	-	-
Investments	-	-	-	-
Other Investing	0	0	0	0
Cash from Financing+	119.4K	470.08K	3.86M	6.34M
Debt Issued (Net)	-	-	-	-
Equity Issued (Net)	-	-	-	-
Dividends Paid	0	0	0	0
Share Repurchases	-	-	-	-
Other Financing	119.4K	7.69K	-310.38K	-396.64K
Net Change in Cash	-	-	-	-
Free Cash Flow+	-119.4K	-468.66K	-3.86M	-5.07M
FCF Margin %	-	-	-	-
FCF Growth %	-	-2.93%	-7.24%	-0.31%
FCF per Share	-0.00	-0.02	-0.13	-0.17
FCF Conversion (FCF/Net Income)	0.86x	0.55x	0.30x	0.31x
Interest Paid	0	0	0	0
Taxes Paid	0	0	0	0

Key Ratios

Metric	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-1045.36%	-810.18%
Return on Invested Capital (ROIC)	-	-	-185.88%	-610.42%
Debt / Equity	-	-	0.03x	0.15x
Interest Coverage	-	-	-2.40x	-
FCF Conversion	0.86x	0.55x	0.30x	0.31x

Frequently Asked Questions

Growth & Financials

Telomir Pharmaceuticals, Inc. Common Stock (TELO) grew revenue by 0.0% over the past year. Growth has been modest.

Telomir Pharmaceuticals, Inc. Common Stock (TELO) reported a net loss of $11.3M for fiscal year 2024.

Dividend & Returns

Telomir Pharmaceuticals, Inc. Common Stock (TELO) has a return on equity (ROE) of -810.2%. Negative ROE indicates the company is unprofitable.

Telomir Pharmaceuticals, Inc. Common Stock (TELO) had negative free cash flow of $3.1M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener